Signal transduction is the process by which a cell can convert an input into an appropriate output [51] , for example conversion of muscarinic stimulation of glandular tissue into a secretory response. There are four elements between input and output in this basic system (see fig. 1 ). The agonist or first messenger (which may be a neurotransmitter or hormone) interacts with a specific cell surface receptor. The conformational change occurring in the receptor protein as a consequence of agonist binding enables the receptor to interact with the second element in the system, the G protein. The G protein transduces the signal to an amplifying enzyme (third component) whose activity elaborates a second messenger, the final component of the system. The second messenger will activate a cascade of enzymes which ultimately lead to an increase in protein phosphorylation and an output or response.
been named the magnificent seven) with three extracellular loops and three intracellular loops; the carboxy terminus of the protein is intracellular and the N terminus is extracellular. The remainder of this review will consider the muscarinic receptor family ( fig. 2) [27, 59] .
The muscarinic receptors are a family of five subtypes M1-M5; all have different amino acid sequences, but there is a great deal of similarity (homology) between certain of the subtypes in precise areas of the protein. For example, the third intracellular loop of the proteins show greatest homology between Ml, M3 and M5 and between M2 and M4, but not between these groups. Also, Ml, M3 and M5 subtypes couple to inositol polyphosphate generation and M2 and M4 subtypes inhibit the generation of cAMP. These findings point to the third intracellular loop of the protein being the site at which subtype selective messenger linkage occurs [34, 59] (i.e. the site of receptor G protein interaction). In an elegant series of experiments where chimeric muscarinic receptors have been created, it has been shown that if an M2 receptor is constructed with an M3 third intracellular loop, this M2 receptor (with a normal pharmacological profile) couples to the wrong second messenger system, inositol polyphosphate generation [68, 69] . There has also been suggestion, but no definite consensus, that the C terminal region may also be involved in the interaction with G protein [68] . The site of agonist interaction appears to involve spanning domains 3, 6 and 7, and if the receptor is redrawn in the helical wheel configuration, as shown in figure 2 ("birds eye view" of the extracellular surface of the membrane), agonist interaction may be seen clearly.
To date, there have been at least 100 G proteincoupled receptors identified (many have been cloned and sequenced) and for many the pharmacology or function has not been established [67] . Indeed the field is advancing so rapidly that in the period between writing this article and it going to press, many more receptor(s) will have come under the "cloners" scrutiny. Table I shows some of these G protein-coupled receptors and the second messenger system to which they couple. 
Guanine nucleotide binding (G) proteins are a group of membrane associated proteins that transduce the agonist-receptor interaction into an intracellular response via interaction with a specific effector enzyme ( fig. 1) [8, 9, 44, 49, 64] . As the name suggests, these proteins bind the guanine nucleotides GDP and GTP. In the inactive state, GDP is bound and when activated GDP is exchanged for GTP. G proteins are heterotrimers (i.e. they are composed of three structurally distinct subunits, alpha, beta and gamma). The beta and gamma subunits show good homology across different G proteins. G proteins are best distinguished by differences in their alpha subunits (table II) . Beta and gamma subunits are probably involved in anchoring the protein in the plasma membrane, whereas the alpha subunit has a number of functions to perform. It must interact with the receptor (see fig. 2 ), it must interact with the effector enzyme (e.g. adenylyl cyclase) and it must possess GTPase activity to enable inactivation.
Next we consider the sequence of events between agonist-receptor interaction and activation of the effector enzyme, the G protein cycle ( fig. 3) [64] . Agonist interaction with the receptor causes a conformational change in the receptor protein to enable interaction with the G protein. Bound GDP (inactive) is exchanged for intracellular GTP ( fig.  3A) . The alpha subunit dissociates from the betagamma complex ( fig. 3B ). Alpha-GTP may then interact with the effector enzyme ( fig. 3c ). The alpha subunit displays GTPase activity which converts bound GTP to GDP ( fig. 3D ) and inactivates the G protein. Finally, the alpha and beta-gamma subunits reassociate and the cycle begins anew. The cycle can be modified pharmacologically using non-hydrolysable analogues of GTP (GTP [S] and Gpp(NH)p); these cannot be broken down by the GTPase intrinsic to the alpha subunit and thus provide prolonged stimulation of the effector enzyme. The drawback with these analogues is that they are membrane impermeant and may only be used in membranes or permeabilized cells [70] .
The activity of two bacterial toxins has simplified the classification of G proteins and has given clues to the mechanisms of disease. Pertussis toxin interacts with a class of Gj-like G proteins (e.g. Gi and G o ). Cholera toxin interacts with a different class of G proteins (e.g. G s ). In the case of pertussis toxin, this toxin ADP-ribosylates G ( (like) G proteins and prevents their interaction with the effector enzyme. Cholera toxin causes prolonged interaction of the G protein with the effector enzyme. For example, in diarrhoea associated with cholera, overstimulation of cAMP formation in the gut leads to oversecretion of water and electrolytes [64] . Recently, G proteins have been more accurately identified and classified using G protein specific antibodies [49] .
ADENYLYL CYCLASE-CAMP
Adenylyl cyclase is the membrane bound enzyme that converts intracellular ATP to the second messenger cAMP [41] [42] [43] . Increased concentrations of cAMP activate a specific protein kinase enzyme (protein kinase A) and cause the phosphorylation events that lead to cellular responsiveness. Examples of cAMP coupled receptors are shown in ergic receptors, couple via the stimulatory G protein (G s ) to activate the enzyme and increase the intracellular concentration of cAMP. Inhibitory receptors (R,), for example opioid and alpha 2 adrenergic receptors, couple via the inhibitory G protein (Gj) and reduce cAMP formation. The biological signal produced by cAMP is terminated by cellular phosphodiesterase activity converting cAMP to 5'-AMP. There are several ways in which we may interfere with the system pharmacologically. The intracellular concentration of cAMP can be increased artificially using the adenylyl cyclase activator forskolin ( fig. 5 ) and cAMP breakdown may be inhibited by phosphodiesterase inhibition (e.g. using the methylxanthine, IBMX) [41] [42] [43] . Indeed, in a system where cAMP breakdown is inhibited and adenylyl cyclase is activated with forskolin, many groups have examined the G, linked inhibition of cAMP formation. An example of such a study is shown in table III, comparing opioid and alpha, receptor mediated cAMP inhibition [38] . As men- tioned above, cAMP can be increased by the action of cholera toxin on G s and the inhibitory action of G f linked receptors may be prevented by pertussis toxin (table III) [64] .
Activation of a wide variety of cell surface receptors leads to the breakdown of a specific membrane phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2) to yield two biologically active second messengers, inositol-l,4,5-triphosphate (Ins(l,4,5)P 3 ) and diacylglycerol (DAG) [5-7, 14, 30,40] . The breakdown of PIP2 is achieved by a membrane associated enzyme phospholipase C. In common with the cAMP signalling system, the receptor is coupled to the effector (phospholipase C) by a transducing G protein. This G protein is, in many cases, the recently identified G q [62] (fig. 6 ). There is now irrefutable evidence that Ins(l,4,5)P 3 releases Ca 2+ from an intracellular store [30, 50, 52 ] by interaction with a specific intracellular receptor protein (which has now been cloned and sequenced) [22] . The increased concentration of this important second messenger, Ca 2+ , leads to activation of calcium-calmodulin-dependent protein kinase and subsequent protein phosphorylation. There have also been suggestions that Ins(l,4,5)P 3 may be involved in the gating of extracellular Ca 2+ [29] . The intracellular Ca 2+ signal produced by agonists linked to PIP2 hydrolysis is often complex [36, 37, 40] . For example, in SH-SY5Y human neuroblastoma cells, stimulation of M3 muscarinic receptors leads to a biphasic increase in intracellular Ca 2+ ( fig. 7 ) [36] . The peak phase is a result of release of Ca 2+ from an intracellular Ins(l,4,5)P 3 sensitive store and the plateau phase is caused by Ca 2+ entry across the plasma membrane [36, 39] .
Measurements of Ins(l,4,5)P 3 mass concentration ( fig. 7) , show close correlation with the Ca 2+ signal, indicating the involvement of this polyphosphate in the release of stored Ca 2+ [35, 36] . Indeed, in permeabilized SH-SY5Y cells, exogenous Ins(l,4,5)P 3 has been shown to release stored Ca 2+ [71] . It appears that the long lasting increase in Ins(l,4,5)P 3 ( fig. 7) , is the result of Ca 2+ activation of phospholipase C [60] , the source of this Ca 2+ being via influx [40] (see below). Intracellular Ins(l,4,5)P 3 produced by receptor stimulation is handled by the cell in two different ways. First, it may be further phosphorylated by a 3-kinase enzyme to produce inositol 1,3,4,5-tetrakisphosphate (Ins(l,3,4,5)P 4 ) and a variety of roles have been ascribed to this polyphosphate [30] . The biological signals produced by both of these second messengers are terminated by a 5-phosphatase enzyme to yield the inactive Ins(l,3,4)P 3 and Ins(l,4)P 2 from Ins(l,3,4,5)P 4 and Ins(l,4,5)P 3 , respectively. These polyphosphate intermediates are subsequently dephosphorylated to inositol which can then be re-incorporated into the membrane pool of phosphoinositides and thus completes the cycle [60] .
It is assumed that overactivity of the polyphosphoinositide cycle occurs in manic depressive illness and that the anti-manic drug, Li + , blocks inositol monophosphatase, thereby reducing the membrane pool of phosphoinositides and interrupting the cycle [53] . The cycle can be regulated in several subtle ways, the most notable being the Ca 2+ sensitivity of the enzyme phospholipase C [60] , in that Ca 2+ released from intracellular stores or gated from the extracellular space may activate phospholipase C and cause further generation of Ins(l,4,5)P 3 and DAG. DAG is a lipid soluble second messenger molecule which remains in the plane of the plasma membrane to activate another membrane bound enzyme, protein kinase C, and once again this enzyme causes protein phosphorylation and cellular responsiveness. It is noteworthy that phosphoinositides have also been found in the nuclear membrane [15] . Their function is unclear but they could be involved in intranuclear Ca 2+ homeostasis. Therefore, by occupation of a receptor linked to phospholipase C, it is evident that a variety of second messengers may be generated and, depending on the intracellular targets present, a diverse array of cell types can produce a diverse array of cellular responses.
The second messenger systems described so far should not be considered in isolation, but as a complex interacting network with which a cell may turn receptor stimulation into a finely tuned cellular response. For example, the identification of Ca 2+ sensitive species of adenylyl cyclase (see [17, 24, 33] and references therein) makes cross talk between sensitive dye fura-2) to carbachol (O) is biphasic with the peak a result of Ca 2+ release from intracellular stores and the plateau phase a result of Ca 2+ entry. The Ins(l,4,5)P 3 (#) time course is also shown. Ins(l,4,5)P 3 peaks before Ca 2+ , indicating the former mediates release of the latter. The increased concentrations of Ins(l,4,5)P 3 at 2 min result from Ca 2 * entry stimulating phospholipase C (data taken from [35, 36] It is also worth noting that other second messenger systems do exist, for example guanylate cyclasecGMP, but space does not permit a full description and the reader is referred to the following articles [25, 32] . AMPLIFICATION From the preceding sections it is clear that with a multistep signal transduction process, scope exists for amplification of an incoming signal. Consider the possibility that one molecule of glucagon binding to its receptor may interact with 10 molecules of G s and each molecule of G s may interact with 10 molecules of adenylyl cyclase to produce 10 molecules of cAMP: the initial signal has been amplified 10 3 fold. Hence a sensitive response can be mounted to small levels of stimulation. It is not hard to imagine that a large input could be catastrophic in that intracellular messengers could build up to concentrations that would "swamp" the cell. Fortunately, amplification is rarely so large and reduction steps (using the above example, not every G protein will find a molecule of adenylyl cyclase to activate) must occur.
INTERACTION OF ANAESTHETIC AGENTS WITH SIGNAL TRANSDUCTION
In agreement with the Meyer-Overton "rule" that anaesthetic potency correlates with lipid solubility [48, 56, 63] , Franks and Lieb suggested that the site of action of anaesthetic agents is likely to be a cellular lipid or a cellular component surrounded by lipid. The most obvious target appears to be the plasma membrane where anaesthetics could potentially: (a) increase membrane fluidity, (b) increase membrane phase transition, (c) cause changes in the dimensions [55]
[54] [1] of the membrane, (d) alter membrane permeability or (e) interact with proteins [20, 21] . The latter possibility appears the most attractive but are anaesthetic agents capable of interacting with proteins directly or indirectly via action at the lipidprotein interface? It is important to remember that the cell has more than one lipid bilayer and the cell membrane may not be the only site of action. We must also look to the nucleus, mitochondria, endoplasmic reticulum, secretory granules, etc, all of which are surrounded by membranes, as possible targets.
There are various steps in the signal transduction pathway as possible sites of action (many of which are in the lipid environment of the plasma membrane) of anaesthetic (particularly volatile) agents. Membrane ion channels have been deliberately excluded as they will be covered by other reviews in this issue. It is possible to identify four target groups (see figs 1, 8) : (a) binding of agonist to receptor, (b) G protein function, (c) effector activity (adenylyl cyclase, phospholipase C) and (d) other intracellular sites (Ca 2+ stores, cellular kinases). There have been several studies detailing the effects of anaesthetic agents on ligand-receptor binding. However, all have produced variable and what appear to be tissue-specific differences. The most widely studied systems are adrenergic, muscarinic and opioid, and the results of these are summarized in table IV [1-3, 54, 55] .
It is worth defining some of the terms used with reference to receptor binding. Umax (receptor density) and the affinity of a drug (its K A ) may be determined directly where a radiolabelled ligand is available. This is accomplished by adding increasing concentrations in the presence of a fixed number of receptors until the specific receptor binding saturates (Bmax): K A is the concentration of ligand that produces half maximum binding [58] . The K 6 of a ligand is like a signature for that particular receptor and if an anaesthetic agent were to alter the K A of a ligand for its receptor, it is likely to be interfering with ligand-receptor binding. It is also possible that anaesthetic agents could alter Bmax, by either increasing (perhaps by up-regulation) or decreasing (perhaps by producing desensitization) receptor density. Drug affinity may also be calculated using a fixed concentration of radiolabelled ligand and increasing concentrations of unlabelled drug, which displace the label. The concentration producing half maximum displacement is related to affinity [12] . Halothane at clinical concentrations has no effect on adrenoceptor (alpha or beta) binding to either brain or cardiac tissue [2, 3] , yet this volatile agent has variable effects on muscarinic receptor affinity (table  IV) [1, 2] . Opioid receptors are of obvious clinical importance as opioids are commonly given in combination with inhalation anaesthetics. Halothane (and nitrous oxide) appear to decrease both \i and K receptor affinity and also K receptor Bmax in guineapig brain [55] . The consequences of these effects are unclear but may be mutually antagonistic! Clearly this is an area in need of further investigation.
Another vital component in the signal transduction pathway that is intimately associated with the plasma membrane is the G protein. Studies on the effects of opioids on Gi/G 0 are numerous, but in these examples the agonist "needs" the G protein to transduce its signal [13, 47] . Unfortunately, for volatile anaesthetics the effects are less well known and have been addressed by looking at modulation of the agonist-receptor-G protein interaction. As described above, the affinity of an unlabelled agonist may be determined by displacement of a labelled drug: if this experiment is performed in washed membranes (no GTP), then two populations of receptors exist, those pre-coupled to the G protein (high affinity for agonist) and free receptors (low affinity for agonists). If GTP is added (see fig. 3 ), G protein activation occurs and the high affinity binding moves to low affinity (i.e. G protein precoupled will dissociate) [64] .
Thus in an experiment where there is a shift in the proportion of high affinity receptors to low affinity upon addition of GTP, it would be possible to examine any gross effects of volatile anaesthetics on G protein function. In two separate studies (both in rat brain), halothane was shown to either eliminate the high-low affinity shift or to have no effect [1, 2] upon carbachol binding to muscarinic receptors. Halothane appears to have no effect on alpha and beta adrenoceptor G protein interaction [2] .
Okuda, Miyazaki and Kuriyama adopted a different approach to study G proteins. They Ref.
[23]
[31]
[46]
[54] [4] [66] [2] examined the binding of the non-hydrolysable analogue of GTP, [ 3 H]Gpp(NH)p (this is not broken down by the intrinsic GTPase and produces long lasting stimulation of the effector enzyme). Halothane and ketamine had no effect on the binding of [ 3 H]Gpp(NH)p, but at large concentrations, ethanol produced significant inhibition [54] . In a curious report, examining the interaction of halothane and morphine on the guineapig ileum, it was shown clearly that the relaxant effects of morphine were unaffected by pertussis toxin pretreatment, yet the relaxant effect of halothane was reduced markedly (half maximum inhibition shift from 2 % halothane to an extrapolated 9% halothane) [57] . The mechanisms underlying this response are unclear, but pertussis toxin was administered to the whole animal. At the time of writing this review, the author is unaware of any reports of anaesthetic interaction with the intrinsic GTPase associated with the alpha subunit. Clearly inhibition would prolong the activation of the effector component of transduction.
The effects of halothane on cAMP formation have been reported by several authors using a variety of experimental paradigms. These vary from measurements of whole tissue contents after anaesthesia [31, 46, 66] to examining the effects on agonistdriven responses [2, 4, 23, 54] (table V) . What is clear, and in accord with previous sections, is that no consistent effects have been observed. In neuronal tissues, halothane increases cAMP concentrations in vivo [31, 46] , decreases noradrenaline stimulated cAMP formation [54] or is ineffective [2] . In cardiac tissue, a general decrease is observed [23, 66] , whilst in the liver, halothane increases both basal and glucagon stimulated cAMP formation [4] . These experiments are attempting to mimic (or to examine directly) what would happen in vivo. They do not address the question, what is the effect of halothane on adenylyl cyclase ? From the preceding section it is clear that halothane may interact with receptor binding and may interact with the G protein. Studies in a simple preparation where adenylyl cyclase may be activated directly, for example with forskolin, may shed some light as to the action of halothane (and other volatile agents). It may be that the tissue differences observed reflect differences in the distribution of Ca 2+ sensitive and insensitive forms of adenylyl cyclase [17, 24, 33] . Therefore, rather than acting directly, halothane may act indirectly by increasing intracellular Ca 2+ [28] and activating a Ca 2+ sensitive adenylyl cyclase. This idea needs testing. Halothane has also been shown to decrease cerebellar cGMP concentrations and motor activity [65] .
Three studies on the effect of halothane on inositol polyphosphate formation are of interest [2, 26, 61] [53] . Studies using the newly available mass assays are needed [10, 11] .
Bazil and Minneman [2] were unable to demonstrate any effects of halothane (1.25%) on basal, noradrenaline, carbachol, histamine or serotonin stimulated inositol phosphate formation in rat brain cortical slices using a Li + block. In a recent study, Sill and colleagues showed that halothane interferred with vasopressin stimulated inositol phosphate formation and subsequent generation of an intracellular Ca 2+ signal in A7r5 cultured vascular smooth muscle cells. Halothane, 1 % and 2 %, decreased vasopressin stimulated inositol phosphate formation by 46 % and 61 %, respectively. The intracellular Ca 2+ response consisted of Ca 2+ entry and Ca 2+ release from intracellular (presumably Ins(l,4,5)P 3 sensitive) stores. Halothane reduced significantly both components. A decrease in Ca 2+ released from intracellular stores is consistent with a reduction in the concentration of Ins(l,4,5)P 3 , although this polyphosphate was not measured directly [61] . Also, using the Li + block technique, Hassessian, Prat and Couture demonstrated recently that pentobarbitone caused significant inhibition of basal, substance P stimulated and carbachol stimulated inositol phosphate formation in spinal cord and cerebral cortex of the rat [26] . Some of the remaining possible targets must lie in the cytoplasm, cellular kinases that are activated by intracellular second messengers, mitochondria and possibly intracellular Ca 2+ stores [16, 28] . There is evidence from the study of malignant hyperthermia to suggest an interaction of volatile anaesthetics with intracellular Ca 2+ stores [45] . Certainly halothane has been shown to release Ca 2+ from internal stores in normal tissue and to a greater extent in malignant hyperthermia [18, 19] . What is the nature of this interaction? The intracellular Ins(l,4,5)P 3 sensitive store is a membrane bound structure with an Ins(l,4,5)P 3 receptor, which probably acts as a Ca 2+ channel, located on its surface [22, 52] . The previous discussion could equally relate to this structure with effects, for example on membrane fluidity, interaction with protein or the Ins(l,4,5)P 3 receptor.
Only with answers to the basic questions highlighted ( fig. 8 ) in this and other reviews may we begin to unravel the complexities underlying the state of anaesthesia. The clues are there to be investigated further, and hopefully over the next few years an hypothesis to explain the mechanisms of anaesthesia will emerge.
